AstraZeneca PLC (AZN)vsKamada (KMDA)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
KMDA
Kamada
$7.92
-0.88%
HEALTHCARE · Cap: $477.13M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 31887% more annual revenue ($61.37B vs $191.85M). AZN leads profitability with a 17.0% profit margin vs 11.6%. KMDA appears more attractively valued with a PEG of 0.62. KMDA earns a higher WallStSmart Score of 67/100 (B-).
AZN
Buy60
out of 100
Grade: C+
KMDA
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Margin of Safety
+15.3%
Fair Value
$9.87
Current Price
$7.92
$1.95 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Revenue surging 22.7% year-over-year
Earnings expanding 23.1% YoY
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : KMDA
The strongest argument for KMDA centers on Debt/Equity, PEG Ratio, Price/Book. Revenue growth of 22.7% demonstrates continued momentum. PEG of 0.62 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : KMDA
The primary concerns for KMDA are Market Cap.
Key Dynamics to Monitor
AZN profiles as a mature stock while KMDA is a growth play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.20 — expect wider price swings.
KMDA is growing revenue faster at 22.7% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
KMDA scores higher overall (67/100 vs 60/100) and 22.7% revenue growth. AZN offers better value entry with a 18.4% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Kamada
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Kamada Ltd. develops, produces and markets plasma-derived protein therapies for orphan indications. The company is headquartered in Rehovot, Israel.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?